A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) (ENESTnd)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT00471497
First received: May 7, 2007
Last updated: October 14, 2013
Last verified: October 2013
  Purpose

In this study, the efficacy and safety of two nilotinib doses, 300 mg twice daily and 400 mg twice daily, will be compared with imatinib 400 mg once daily in newly diagnosed patients with Philadelphia chromosome-positive (Ph+) Chronic Myelogenous Leukemia in the chronic phase (CML-CP).


Condition Intervention Phase
Myelogenous Leukemia, Chronic
Drug: nilotinib
Drug: imatinib
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase III Multi-center, Open-label, Randomized Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Molecular Response Rate (MMR) at 12 Months [ Time Frame: Baseline, 12 months ] [ Designated as safety issue: No ]
    Rate of MMR is defined as <= 0.1% BCR-ABL/ABL ratio by international scale (IS), measured by real-time quantitative polymerase chain reaction (RQ-PCR) which corresponds to a ≥ 3 log reduction of BCR-ABL transcript from standardized baseline. BCR-ABL = fusion gene from BCR (breakpoint cluster region gene/BCR gene product) and ABL (Abelson protooncogene)


Secondary Outcome Measures:
  • Rate of Durable MMR at 24 Months. [ Time Frame: Baseline, 24 months ] [ Designated as safety issue: No ]
  • Rate Reduction in BCR-ABL Transcript Levels in Nilotinib Treatment Arms With Imatinib at 12 Months [ Time Frame: Baseline, 12 months ] [ Designated as safety issue: No ]
  • Rate of Complete Cytogenetic Response (CCyR) in Nilotinib Treatment Arms With Imatinib at 12 Months [ Time Frame: Baseline, 12 months ] [ Designated as safety issue: No ]

Enrollment: 846
Study Start Date: July 2007
Estimated Study Completion Date: October 2018
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Imatinib 400 mg QD
Patients randomized to this arm were to receive 400 mg imatinib once a day (QD). If the patient required a dose escalation from 400 mg/day, the patient was to receive 400 mg imatinib twice daily orally. Imatinib was taken with food and a large glass of water. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits during the study. In cases of vomiting doses were not to be repeated.
Drug: imatinib
Imatinib was supplied as 100 mg and 400 mg tablets and administered orally at 400 mg QD (once a day).
Other Name: STI571
Experimental: Nilotinb 300 mg BID
Patients who were randomized to this arm were to receive nilotinib 300 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.
Drug: nilotinib
Nilotinib was supplied as 50 mg, 150 mg and 200 mg hard gelatin capsules and administered orally at 300 mg BID (twice a day) or 400 mg BID (twice a day)depending on the randomized dose.
Other Name: AMN107
Experimental: Nilotinib 400 mg BID
Patients who were randomized to this arm were to receive nilotinib 400 mg twice a day (BID) by mouth each morning and evening approximately 12 hours apart. If the morning or evening dose was delayed for more than 4 hours, the patient was to skip this dose and resume dosing with the next dose as per the original schedule in order to prevent overdosing. No imatinib washout period was necessary prior to administration of nilotinib. Nilotinib was not to be taken with food. No food was to be consumed for at least 2 hours before the dose was taken and no additional oral intake other than water was to be consumed for at least one hour after the dose was taken. Patients were instructed to swallow capsules whole with a full 8 ounce glass of water, and not to chew them. All patients were to avoid grapefruit, star fruit, pomegranate and Seville oranges or juices and products containing these fruits. Vomited doses were not to be repeated.
Drug: nilotinib
Nilotinib was supplied as 50 mg, 150 mg and 200 mg hard gelatin capsules and administered orally at 300 mg BID (twice a day) or 400 mg BID (twice a day)depending on the randomized dose.
Other Name: AMN107

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • ECOG 0, 1, or 2.
  • Patients with CML-CP within 6 months of diagnosis (date of initial diagnosis is the date of first cytogenetic analysis). Standard conventional cytogenetic analysis must be done on bone marrow. (FISH cannot be used)
  • Diagnosis of chronic myelogenous leukemia in chronic phase with cytogenetic confirmation of Philadelphia chromosome of (9;22) translocations (presence of BCR-ABL: a review of a minimum 20 metaphases is required.).
  • Documented chronic phase CML will meet all the criteria defined by:
  • < 15% blasts in peripheral blood and bone marrow
  • < 30% blasts plus promyelocytes in peripheral blood and bone marrow
  • < 20% basophils in the peripheral blood
  • ≥ 100 x 109/L (≥ 100,000/mm3) platelets
  • No evidence of extramedullary leukemic involvement, with the exception of hepatosplenomegaly
  • Adequate end organ function as defined by:
  • Total bilirubin < 1.5 x ULN
  • SGOT and SGPT < 2.5 x ULN
  • Creatinine < 1.5 x ULN
  • Serum amylase and lipase ≤ 1.5 x ULN
  • Alkaline phosphatase ≤ 2.5 x ULN unless considered tumor related.
  • Female patients of childbearing potential must have a negative serum pregnancy test within 7 days before initiation of study drug.
  • Patients must have the following laboratory values (≥ LLN (lower limit of normal) or corrected to within normal limits with supplements prior to the first dose of study medication.):
  • Potassium ≥ LLN
  • Magnesium ≥ LLN
  • Phosphorus ≥ LLN
  • Total calcium (corrected for serum albumin) ≥ LLN.
  • Ability to provide written informed consent prior to any study related screening procedures being performed.

Exclusion criteria:

  • Patients who are considered to be Philadelphia chromosome negative because they do not have a confirmed cytogenetic diagnosis of Philadelphia chromosome (9,22 translocation) positive CML.
  • Previously documented T315I mutations.
  • Treatment with tyrosine kinase inhibitor(s) prior to study entry is not allowed, except in the following situation: in emergent cases where the patient requires disease management while awaiting study start, commercial supplies of Gleevec/Glivec at any dose may be prescribed to the patient but for no longer than 2 weeks in duration.
  • Any medical treatment for CML prior to study entry for longer than 2 weeks with the exception of hydroxyurea and/or anagrelide
  • Impaired cardiac function including any one of the following:
  • LVEF < 45% or below the institutional lower limit of the normal range (whichever is higher) as determined by locally read echocardiogram
  • Inability to determine the QT interval on ECG
  • Complete left bundle branch block
  • Use of a ventricular-paced pacemaker
  • Congenital long QT syndrome or a known family history of long QT syndrome.
  • History of or presence of clinically significant ventricular or atrial tachyarrhythmias
  • Clinically significant resting bradycardia (<50 beats per minute)
  • QTc > 450 msec on the average of three serial baseline ECG (using the QTcF formula) as determined by central reading. If QTcF >450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc
  • History of clinically documented myocardial infarction
  • History of unstable angina (during the last 12 months)
  • Other clinically significant heart disease (e.g., congestive heart failure or uncontrolled hypertension).
  • Known cytopathologically confirmed CNS infiltration (in absence of suspicion of CNS involvement, lumbar puncture not required).
  • Severe or uncontrolled medical conditions (i.e. uncontrolled diabetes, active or uncontrolled infection).
  • History of significant congenital or acquired bleeding disorder unrelated to cancer.
  • Previous radiotherapy to ≥ 25% of the bone marrow.
  • Major surgery within 4 weeks prior to Day 1 of study or who have not recovered from prior surgery.
  • Treatment with other investigational agents (defined as not used in accordance with the approved indication) within 30 days of Day 1.
  • History of non-compliance to medical regimens or inability to grant consent.
  • Use of therapeutic coumarin derivatives (i.e., warfarin, acenocoumarol, phenprocoumon)
  • Patients with another primary malignancy except if the other primary malignancy is neither currently clinically significant or requiring active intervention
  • Patients actively receiving therapy with strong CYP3A4 inhibitors (e.g., erythromycin, ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, mibefradil) and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug. See link for complete list of these medications: http://medicine.iupui.edu/flockhart/table.htm. Novartis must be contacted if a patient needs to be started on any of these drugs during study treatment.
  • Patients actively receiving therapy with strong CYP3A4 inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbitol, St. John's Wort) and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug. See link for complete list of these medications: http://medicine.iupui.edu/flockhart/table.htm. Novartis must be contacted if a patient needs to be started on any of these drugs during study treatment.
  • Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass surgery)
  • History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis.
  • Acute or chronic liver, pancreatic or severe renal disease considered unrelated to disease.
  • Patients who are currently receiving treatment with any medications that have the potential to prolong the QT interval and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug (Please see http://www.torsades.org/medical-pros/drug-lists/printable-drug-list.cfm for a comprehensive list of agents that prolong the QT interval)
  • Patients who are: (a) pregnant, (b) breast feeding, (c) of childbearing potential without a negative pregnancy test prior to baseline and (d) female of childbearing potential unwilling to use contraceptive precautions throughout the trial (post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential)

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00471497

  Hide Study Locations
Locations
United States, California
University of California at Los Angeles Dept. of Hematology Clinic
Los Angeles, California, United States, 90095
Kaiser Permanente - California Southern Dept of Kaiser South 9
San Diego, California, United States
Kaiser Permanente - California Southern Dept of Kaiser South 3
San Diego, California, United States
Kaiser Permanente - California Southern San Diego Zion Avenue
San Diego, California, United States
Kaiser Permanente - California Northern Kaiser Med
Vallejo, California, United States
Kaiser Permanente - California Northern Vallejo Med Center/Med Offices
Vallejo, California, United States
United States, Colorado
Rocky Mountain Cancer Centers RMCC - Colorado Springs
Greenwood Village, Colorado, United States
United States, Florida
Florida Cancer Specialists Dept. FloridaCancerSpecialists
Fort Myers, Florida, United States, 33901
Advanced Medical Specialties Research Dept.
Miami, Florida, United States, 33176
Florida Cancer Institute Flordia Cancer Affilates
New Port Richey, Florida, United States, 34655
Cancer Centers of Florida PA Cancer Centers of FL
Ocoee, Florida, United States
United States, Illinois
University of Chicago Medical Center Section of Hematology/Oncology
Chicago, Illinois, United States, 60546
United States, Indiana
Indiana Blood and Marrow Institute Dept. of Indiana Blood&Marrow
Beach Grove, Indiana, United States, 46107
United States, Iowa
University of Iowa Hospitals and Clinics Dept.of U of Iowa Hosp&Clinics
Iowa City, Iowa, United States, 52242
United States, Kansas
Kansas City Cancer Center KCCC Business Office
Overland Park, Kansas, United States, 66210
United States, Louisiana
LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Feist-Weiller Cancer Center
New Orleans, Louisiana, United States, 70115
United States, Michigan
Michigan State University / Breslin Cancer Center Breslin Cancer Center
Lansing, Michigan, United States
United States, Missouri
Missouri Cancer Associates Dept. of Boone Hospital Center
Columbia, Missouri, United States, 65201
Hematology Oncology Consultants, Inc. Deptof Hem. Onc.Consunsultants
St. Louis, Missouri, United States, 63136
United States, New Jersey
Hackensack University Medical Center Department of Research
Hackensack, New Jersey, United States, 07601
United States, New York
Memorial Sloan Kettering Cancer Center Clinical Trials Office
New York, New York, United States, 10021
United States, North Carolina
UNC/Lineberg Comprehensive Cancer Center UNC Lineberger Cancer Center
Chapel Hill, North Carolina, United States, 27514
Cancer Centers of North Carolina Cancer Centers of NC-Raleigh
Raleigh, North Carolina, United States, 27609
Wake Forest University Baptist Medical Center Dept. of Industry Research
Winston-Salem, North Carolina, United States, 27157
United States, Ohio
University of Cincinnati / Barrett Cancer Center Dept.of Internal Med.
Cincinnati, Ohio, United States, 45219
Cleveland Clinic Foundation CCF
Cleveland, Ohio, United States, 44195
United States, Oregon
Northwest Cancer Specialists Vancouver Location
Portland, Oregon, United States, 97210
United States, South Carolina
Cancer Centers of the Carolinas CC of C -Eastside
Greenville, South Carolina, United States, 29605
United States, Tennessee
Chattanooga Oncology and Hematology Assoicates, PC Memorial Plaza
Chattanooga, Tennessee, United States, 37404
Tennessee Oncology Dept. of Centennial Medical
Nashville, Tennessee, United States, 37203
United States, Texas
Texas Cancer Center ( Medical City Dallas Hospital)
Dallas, Texas, United States, 75230
Cancer Care Centers of South Texas / HOAST CCC of So.TX- Medical Center
San Antonio, Texas, United States, 78229
Tyler Cancer Center
Tyler, Texas, United States, 75702
United States, Utah
Utah Cancer Specialists
Salt Lake City, Utah, United States, 84103
Argentina
Novartis Investigative Site
La Plata, Buenos Aires, Argentina, B1902AVG
Novartis Investigative Site
Buenos Aires, Argentina, C1221ADC
Austria
Novartis Investigative Site
Salzburg, Austria, 5020
Novartis Investigative Site
Wien, Austria, A-1090
Belgium
Novartis Investigative Site
Bruxelles, Belgium, 1000
Novartis Investigative Site
Charleroi, Belgium, 6000
Novartis Investigative Site
Gent, Belgium, 9000
Novartis Investigative Site
Godinne, Belgium, 5530
Novartis Investigative Site
Leuven, Belgium, 3000
Brazil
Novartis Investigative Site
Brasilia, DF, Brazil, 70330-150
Novartis Investigative Site
Curitiba, PR, Brazil, 80060-900
Novartis Investigative Site
Rio de Janeiro, RJ, Brazil, 20211-030
Novartis Investigative Site
Campinas, SP, Brazil, 13083-970
Novartis Investigative Site
Jaú, SP, Brazil, 17210-080
Novartis Investigative Site
São Paulo, SP, Brazil, 01224-000
Novartis Investigative Site
São Paulo, SP, Brazil, 01401-901
Novartis Investigative Site
São Paulo, SP, Brazil, 05403-000
Canada, British Columbia
Novartis Investigative Site
Vancouver, British Columbia, Canada, V5Z 4E6
Novartis Investigative Site
Vancouver, British Columbia, Canada, V5Z 4E3
Canada, Ontario
Novartis Investigative Site
Toronto, Ontario, Canada, M5G 2M9
Canada, Quebec
Novartis Investigative Site
Québec, Quebec, Canada, G1J 1Z4
Canada
Novartis Investigative Site
Quebec, Canada, G1R 2J6
Colombia
Novartis Investigative Site
Bogotá, Colombia
Czech Republic
Novartis Investigative Site
Olomouc, CZE, Czech Republic, 775 20
Novartis Investigative Site
Praha 2, Czech Republic, 128 20
Denmark
Novartis Investigative Site
Copenhagen, Denmark, DK-2100
Novartis Investigative Site
Vejle, Denmark, DK-7100
Egypt
Novartis Investigative Site
Cairo, Egypt
Finland
Novartis Investigative Site
HUS Helsinki, Finland, FIN-00029
Novartis Investigative Site
Turku, Finland, FIN-20521
France
Novartis Investigative Site
Caen, Cedex, France, 14033
Novartis Investigative Site
Angers, France, 49 033
Novartis Investigative Site
Bordeaux, France, 33076
Novartis Investigative Site
Créteil, France, 94010
Novartis Investigative Site
Grenoble, France, 38043
Novartis Investigative Site
Lille, France, 59037
Novartis Investigative Site
Marseille, France, 13273
Novartis Investigative Site
Nantes, France, 44035
Novartis Investigative Site
Nice Cedex, France, 06202
Novartis Investigative Site
Paris, France, 75475
Novartis Investigative Site
Pierre-Benite Cédex, France, F-69495
Novartis Investigative Site
Poitiers, France, Poitiers
Novartis Investigative Site
Rennes, France, 35019
Novartis Investigative Site
Saint Priest en Jarez Cedex, France, 42271
Novartis Investigative Site
Toulouse cedex 9, France, 31059
Novartis Investigative Site
Vandoeuvre les Nancy, France, 54511
Germany
Novartis Investigative Site
Berlin, Germany, 13353
Novartis Investigative Site
Duesseldorf, Germany, 40225
Novartis Investigative Site
Eisenach, Germany, 99817
Novartis Investigative Site
Frankfurt, Germany, 60590
Novartis Investigative Site
Hamburg, Germany, 20246
Novartis Investigative Site
Kiel, Germany, D-24116
Novartis Investigative Site
Koeln, Germany, 50937
Novartis Investigative Site
Leipzig, Germany, 04103
Novartis Investigative Site
Mannheim, Germany, 68169
Novartis Investigative Site
Muenchen, Germany, 81675
Novartis Investigative Site
Ulm, Germany, 89081
Hong Kong
Novartis Investigative Site
Hong Kong, Hong Kong
Hungary
Novartis Investigative Site
Budapest, Hungary, 1097
Italy
Novartis Investigative Site
Alessandria, AL, Italy, 15100
Novartis Investigative Site
Ancona, AN, Italy, 60126
Novartis Investigative Site
Bari, BA, Italy, 70124
Novartis Investigative Site
Bergamo, BG, Italy, 24128
Novartis Investigative Site
Bologna, BO, Italy, 40138
Novartis Investigative Site
Catania, CT, Italy, 95124
Novartis Investigative Site
Firenze, FI, Italy, 50134
Novartis Investigative Site
Genova, GE, Italy, 16132
Novartis Investigative Site
Milano, MI, Italy, 20162
Novartis Investigative Site
Pescara, PE, Italy, 65124
Novartis Investigative Site
Pisa, PI, Italy, 56126
Novartis Investigative Site
Pavia, PV, Italy, 27100
Novartis Investigative Site
Reggio Calabria, RC, Italy, 89124
Novartis Investigative Site
Roma, RM, Italy, 00144
Novartis Investigative Site
Roma, RM, Italy, 00133
Novartis Investigative Site
Roma, RM, Italy, 00161
Novartis Investigative Site
Siena, SI, Italy, 53100
Novartis Investigative Site
Udine, UD, Italy, 33100
Novartis Investigative Site
Napoli, Italy, 80131
Novartis Investigative Site
Napoli, Italy, 80132
Novartis Investigative Site
Perugia, Italy, 06129
Japan
Novartis Investigative Site
Nagoya, Aichi, Japan, 453-8511
Novartis Investigative Site
Nagoya, Aichi, Japan, 466-8560
Novartis Investigative Site
Maebashi, Gunma, Japan, 371-0821
Novartis Investigative Site
Maebashi, Gunma, Japan, 371-8511
Novartis Investigative Site
Sapporo, Hokkaido, Japan, 060-8648
Novartis Investigative Site
Sapporo, Hokkaido, Japan, 003-0006
Novartis Investigative Site
Nishinomiya, Hyogo, Japan, 663-8501
Novartis Investigative Site
Tsukuba, Ibaraki, Japan, 305-8576
Novartis Investigative Site
Kanazawa, Ishikawa, Japan, 920-8641
Novartis Investigative Site
Kumamoto City, Kumamoto, Japan, 860-0811
Novartis Investigative Site
Tsu, Mie, Japan, 514-8507
Novartis Investigative Site
OsakaSayama, Osaka, Japan, 589-8511
Novartis Investigative Site
Suita-city, Osaka, Japan, 565-0871
Novartis Investigative Site
Hidaka, Saitama, Japan, 350-1241
Novartis Investigative Site
Hamamatsu, Shizuoka, Japan, 431-3192
Novartis Investigative Site
Shimotsuke-city, Tochigi, Japan, 329-0498
Novartis Investigative Site
Bunkyo-ku, Tokyo, Japan, 113-8519
Novartis Investigative Site
Bunkyo-ku, Tokyo, Japan, 113-8655
Novartis Investigative Site
Chuo-ku, Tokyo, Japan, 104-0045
Novartis Investigative Site
Shinagawa-ku, Tokyo, Japan, 141-8625
Novartis Investigative Site
Shinjuku-ku, Tokyo, Japan, 160-8582
Novartis Investigative Site
Shinjuku-ku, Tokyo, Japan, 160-0023
Novartis Investigative Site
Akita, Japan, 010-8543
Novartis Investigative Site
Chiba, Japan, 260-8677
Novartis Investigative Site
Hiroshima, Japan, 734-8551
Novartis Investigative Site
Nagasaki, Japan, 852-8501
Novartis Investigative Site
Niigata, Japan, 951-8520
Novartis Investigative Site
Osaka, Japan, 545-8586
Novartis Investigative Site
Saitama, Japan, 330-8503
Korea, Republic of
Novartis Investigative Site
Hwasun-gun, Jeollanam-do, Korea, Republic of, 519-809
Novartis Investigative Site
Seoul, Korea, Korea, Republic of, 110 744
Novartis Investigative Site
Seoul, Korea, Korea, Republic of, 135-710
Novartis Investigative Site
Seoul, Korea, Republic of, 137-701
Novartis Investigative Site
Seoul, Korea, Republic of, 738-736
Novartis Investigative Site
Taegu, Korea, Republic of, 700 - 721
Malaysia
Novartis Investigative Site
Selangor, Malaysia, 68000
Mexico
Novartis Investigative Site
Mexico, Distrito Federal, Mexico, 06726
Novartis Investigative Site
Monterrey, Nuevo León, Mexico, 64450
Netherlands
Novartis Investigative Site
Amsterdam, Netherlands, 1081 HV
Norway
Novartis Investigative Site
Oslo, Norway, NO-0027
Novartis Investigative Site
Trondheim, Norway, 7006
Poland
Novartis Investigative Site
Katowice, Poland, 40032
Novartis Investigative Site
Lublin, Poland, 20-081
Novartis Investigative Site
Rzeszow, Poland, 35-055
Novartis Investigative Site
Warszawa, Poland, 02-097
Novartis Investigative Site
Wroclaw, Poland, 50-367
Portugal
Novartis Investigative Site
Lisboa, Portugal, 1099 - 023
Russian Federation
Novartis Investigative Site
Moscow, Russian Federation, 125167
Novartis Investigative Site
Novosibirsk, Russian Federation, 630091
Novartis Investigative Site
Sankt-Peterburg, Russian Federation, 197022
Singapore
Novartis Investigative Site
Singapore, Singapore, 119228
Novartis Investigative Site
Singapore, Singapore, 169608
Slovakia
Novartis Investigative Site
Bratislava, Slovak Republic, Slovakia, 833 10
Novartis Investigative Site
Bratislava, Slovakia, 851 07
South Africa
Novartis Investigative Site
Bloemfontein, South Africa, 901
Novartis Investigative Site
Cape Town, South Africa, 7925
Novartis Investigative Site
Parktown, South Africa, 2193
Novartis Investigative Site
Pretoria, South Africa, 0027
Novartis Investigative Site
Pretoria, South Africa, 0001
Spain
Novartis Investigative Site
Malaga, Andalucia, Spain, 29010
Novartis Investigative Site
Granada, Andalucía, Spain, 18014
Novartis Investigative Site
Santander, Cantabria, Spain, 39008
Novartis Investigative Site
Salamanca, Castilla y Leon, Spain, 37007
Novartis Investigative Site
Barcelona, Cataluna, Spain, 08035
Novartis Investigative Site
Barcelona, Catalunya, Spain, 08036
Novartis Investigative Site
Hospitalet de LLobregat, Catalunya, Spain, 08907
Novartis Investigative Site
Valencia, Comunidad Valenciana, Spain, 46010
Novartis Investigative Site
La Coruna, Galicia, Spain, 15006
Novartis Investigative Site
Santiago de Compostela, Galicia, Spain, 15706
Novartis Investigative Site
Elche, Murcia, Spain, 03202
Novartis Investigative Site
San Sebastian, Pais Vasco, Spain, 20014
Novartis Investigative Site
Bilbao, País Vasco, Spain, 48013
Novartis Investigative Site
La Laguna, Santa Cruz de Tenerife, Spain, 38320
Novartis Investigative Site
Madrid, Spain, 28034
Novartis Investigative Site
Madrid, Spain, 28041
Novartis Investigative Site
Madrid, Spain, 28046
Novartis Investigative Site
Madrid, Spain, 28006
Novartis Investigative Site
Valencia, Spain, 46026
Novartis Investigative Site
Zaragoza, Spain, 50009
Sweden
Novartis Investigative Site
Göteborg, Sweden, SE-413 45
Novartis Investigative Site
Luleå, Sweden, SE-971 80
Novartis Investigative Site
Lund, Sweden, SE-221 85
Novartis Investigative Site
Stockholm, Sweden, SE-141 86
Novartis Investigative Site
Stockholm, Sweden, SE-171 76
Novartis Investigative Site
Sundsvall, Sweden, SE-851 86
Novartis Investigative Site
Umeå, Sweden, SE-901 85
Novartis Investigative Site
Uppsala, Sweden, SE-751 85
Novartis Investigative Site
Örebro, Sweden, SE-701 85
Switzerland
Novartis Investigative Site
Genève, Switzerland, 1211
Taiwan
Novartis Investigative Site
Lin-Ko, Taiwan, 33305
Novartis Investigative Site
Niaosong Township, Taiwan, 83301
Novartis Investigative Site
Taipei, Taiwan, 10002
Thailand
Novartis Investigative Site
Bangkok, Thailand, 10330
Novartis Investigative Site
Bangkok, Thailand, 10700
Novartis Investigative Site
Bangkok, Thailand, 10400
Turkey
Novartis Investigative Site
Adana, Turkey, 01330
Novartis Investigative Site
Ankara, Turkey, 06500
Novartis Investigative Site
Istanbul, Turkey, 34303
Novartis Investigative Site
Izmir, Turkey, 35340
United Kingdom
Novartis Investigative Site
Glasgow - Scotland, United Kingdom, G12 OYN
Novartis Investigative Site
Leeds, United Kingdom, LS9 7TF
Novartis Investigative Site
Liverpool, United Kingdom, L7 8XP
Novartis Investigative Site
London, United Kingdom, W12 0HS
Novartis Investigative Site
Nottingham, United Kingdom, NG5 1BP
Venezuela
Novartis Investigative Site
Caracas, Distrito Capital, Venezuela, 1010
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Additional Information:
No publications provided by Novartis

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier: NCT00471497     History of Changes
Other Study ID Numbers: CAMN107A2303, 2007-000208-34
Study First Received: May 7, 2007
Results First Received: April 10, 2013
Last Updated: October 14, 2013
Health Authority: United States: Food and Drug Administration
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Austria: Ethikkommission
Belgium: Federal Agency for Medicinal Products and Health Products
Brazil: Ministry of Health
Canada: Health Canada
Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos
Czech Republic: State Institute for Drug Control
Denmark: Danish Medicines Agency
Egypt: Ministry of Health and Population
Finland: Finnish Medicines Agency
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Federal Institute for Drugs and Medical Devices
Hong Kong: Department of Health
Hungary: Research Ethics Medical Committee
Italy: Ministry of Health
Japan: Pharmaceuticals and Medical Devices Agency
Korea: Food and Drug Administration
Malaysia: Ministry of Health
Mexico: Ministry of Health
Netherlands: Medicines Evaluation Board (MEB)
Norway: Norwegian Medicines Agency
Poland: Ministry of Health
Russia: Ministry of Health of the Russian Federation
Singapore: Clinical Trials & Epidemiology Research Unit (CTERU)
Slovakia: State Institute for Drug Control
South Korea: Korea Food and Drug Administration (KFDA)
Spain: Agencia Española de Medicamentos y Productos Sanitarios
Sweden: Medical Products Agency
Switzerland: Swissmedic
Taiwan: Department of Health
Thailand: Food and Drug Administration
Turkey: Ministry of Health
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Venezuela: Ministry of Health and Social Development

Keywords provided by Novartis:
leukemia
bone marrow
leukemia symptoms
cml
complete blood count
lymphocyte
blood cancer
leukocytes
chronic leukemia
bone marrow biopsy
leukemia research
leukemia cells
bone marrow disease
chronic myeloid leukemia
blood cancer symptoms
white blood cell diseases
chronic myelogenous leukemia
leukemia treatment
leukemia facts
leucemia
facts about leukemia
myelogenous leukemia
newly diagnosed CML
Philadelphia chromosome positive
Ph+
chronic phase
CML-CP

Additional relevant MeSH terms:
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Philadelphia Chromosome
Abnormal Karyotype
Leukemia
Neoplasms by Histologic Type
Neoplasms
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Translocation, Genetic
Chromosome Aberrations
Pathologic Processes
Imatinib
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on October 19, 2014